Premium
Rationale for combination use of targeted agents in ovarian cancer
Author(s) -
Coleman Robert L.,
Kohn Elise C.
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23604
Subject(s) - medicine , ovarian cancer , cancer , clinical trial , oncology , preclinical testing , in vivo , intensive care medicine , bioinformatics , medical physics , microbiology and biotechnology , biology
Current advances in targeted agents for the treatment of ovarian cancer stand on scores of negative clinical studies in tumor types with similar target expression, promising in vitro and in vivo preclinical data, and acceptable safety profiles in their early clinical development. The expanding menu of effective compounds challenges investigators and treating physicians to develop an appropriate rationale for developing novel regimens.